There are findings indicating that Th17 cells and IL-17 play some role in the obesity-related inflammatory processes.63 Pantano et al. prospectively analysed 100 PsA patients receiving secukinumab for 6 months and found that overweight/obese patients (BMI≥ 25) had better clinical response (estimated using Disease Activity in Psoriatic Arthritis [DAPSA] score) than those with BMI<25 (p=0.05).64 In contrast, results from a retrospective study in PsO patients show inferior efficacy of sekucinumab in those with BMI ≥ 30.65 This evidence concerns the gene IL17A and psoriatic arthritis.